Hikma Confirms Partnering Room at BIOCHINA BiOPartnering 2026
18 December 2025
Hikma Confirms Partnering Room at BIOCHINA BiOPartnering 2026
Hikma has officially confirmed its Partnering Room at BIOCHINA BiOPartnering 2026, reinforcing its commitment to connecting with leading Chinese biotech companies and exploring new cross-border collaboration opportunities.
Founded in 1978 and headquartered in London, Hikma Pharmaceuticals is a global multinational pharmaceutical company with a distinctive international expansion strategy. Starting from Jordan, Hikma has built a strong global footprint across multiple regulated and emerging markets.
A Distinctive Global Expansion Path
Hikma initially established a solid foundation in the Middle East and North Africa (MENA), leveraging deep regional knowledge to build stable operations and long-term market presence.
The company then expanded into highly regulated European markets, significantly strengthening its quality standards, regulatory compliance, and operational capabilities.
Through acquisitions and organic growth, Hikma successfully entered the United States, which has since become its largest revenue-generating market. Its high level of vertical integration in the U.S. is widely regarded as a strategic advantage amid ongoing global supply chain volatility.
Strategic Focus for 2025
According to Hikma’s latest updates in 2025, the company’s strategic priorities include:
Strengthening R&D and manufacturing through organizational restructuring and centralized global R&D management, aimed at accelerating product development.
Continuing regional and capacity expansion, with increased investment in countries such as Algeria and Morocco, alongside growth in injectable businesses across Europe and the MENA region.
Optimizing the product portfolio, as the branded pharmaceuticals business shifts from a traditional focus on acute treatments, such as antibiotics, toward oncology and chronic disease therapies.
Core Strengths of Hikma
Hikma operates a diversified business portfolio across three complementary segments: Injectables (42%), Branded (24%), and Generics (33%).
The company holds leading market positions, ranking among the top generic pharmaceutical companies in the United States (including injectables and non-injectables), and among the leading pharmaceutical companies in the Middle East and North Africa.
R&D investment remains strong, with R&D expenditure accounting for 4.5% of core revenue in 2024 and a planned increase of approximately 20% in 2025.
Hikma demonstrates strong manufacturing and compliance capabilities, operating 13 U.S. FDA-approved facilities and 12 EMA-certified plants in Europe.
The company maintains a solid financial position, with approximately USD 1.5 billion in available liquidity.